28 December 2020 (Monday) - Stem Cell Evidence Alert

The nice people at the Stem Cell Evidence Alert sent their update today. I must admit that being on Christmas holiday I didn’t peruse it as much as I might have done… but thalidomide !?! 

That stuff is cropping up with more and more uses…


Risk of relapse in patients receiving azithromycin after allogeneic HSCT.
Kutzke, J. L., et al. (2020) Bone Marrow Transplantation [record in progress].


Fresh versus Frozen Allogeneic Peripheral Blood Stem Cell Grafts: a Successful Timely Option.
Alotaibi, A. S., et al. (2020) American Journal of Hematology [record in progress]

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis.
Atagundus, I. K. et al. (2020) Cancers [record in progress]

Full Donor Chimerism After Allogeneic Hematopoietic Stem Cells Transplant For Myelofibrosis: The Role Of The Conditioning Regimen.
Chiusolo, P., et al. (2020) American Journal of Hematology [record in progress]

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy.
Ljungman, P., et al. (2020) Bone Marrow Transplantation [record in progress]

Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function.
Cuadrado, M. M., et al. (2020) Haematologica [record in progress]

Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Post-transplant Cyclophosphamide in Patients with Acute Leukemia.
Nagler, A., et al. (2020) Clinical Cancer Research [record in progress]

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients.
Oran, B., et al. (2020) Blood Advances [record in progress]

A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
Qayed, M., et al. (2020) Blood [record in progress]

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti, P., et al. (2020) The Lancet. Haematology [record in progress]


No comments:

Post a Comment